MacroGenics, Inc. (MGNX)

NASDAQ: MGNX · IEX Real-Time Price · USD
17.54
-0.97 (-5.24%)
Apr 12, 2024, 4:00 PM EDT - Market closed
-5.24%
Market Cap 1.09B
Revenue (ttm) 58.75M
Net Income (ttm) -9.06M
Shares Out 62.03M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 860,025
Open 18.38
Previous Close 18.51
Day's Range 17.12 - 18.54
52-Week Range 4.29 - 21.88
Beta 2.11
Analysts Strong Buy
Price Target 21.50 (+22.58%)
Earnings Date May 7, 2024

About MGNX

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibod... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 10, 2013
Employees 339
Stock Exchange NASDAQ
Ticker Symbol MGNX
Full Company Profile

Financial Performance

In 2023, MacroGenics's revenue was $58.75 million, a decrease of -61.33% compared to the previous year's $151.94 million. Losses were -$9.06 million, -92.44% less than in 2022.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for MGNX stock is "Strong Buy." The 12-month stock price forecast is $21.5, which is an increase of 22.58% from the latest price.

Price Target
$21.5
(22.58% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

ROCKVILLE, MD, April 03, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibo...

11 days ago - GlobeNewsWire

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibo...

5 weeks ago - GlobeNewsWire

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-...

6 weeks ago - GlobeNewsWire

MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based thera...

6 weeks ago - GlobeNewsWire

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-...

2 months ago - GlobeNewsWire

MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results

ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based thera...

5 months ago - GlobeNewsWire

MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therap...

5 months ago - GlobeNewsWire

MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results

ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...

8 months ago - GlobeNewsWire

MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-b...

9 months ago - GlobeNewsWire

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results

ROCKVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the ...

1 year ago - GlobeNewsWire

MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

1 year ago - GlobeNewsWire

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)

ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th...

1 year ago - GlobeNewsWire

MacroGenics Provides Corporate Update and 2022 Financial Results

ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th...

1 year ago - GlobeNewsWire

Synaffix Announces Expansion of ADC Collaboration with MacroGenics

MacroGenics adds up to four ADC programs MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix's linker-payload technologies Expanded collaboration incl...

1 year ago - PRNewsWire

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu...

1 year ago - GlobeNewsWire

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu...

1 year ago - GlobeNewsWire

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

ROCKVILLE, MD, Feb. 13, 2023 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu...

1 year ago - GlobeNewsWire

MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th...

1 year ago - GlobeNewsWire

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...

1 year ago - GlobeNewsWire

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th...

1 year ago - GlobeNewsWire

MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results

ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...

1 year ago - GlobeNewsWire

MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeut...

1 year ago - GlobeNewsWire

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

FOSTER CITY, Calif.

Other symbols: GILD
1 year ago - Business Wire

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results

ROCKVILLE, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...

1 year ago - GlobeNewsWire

MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeuti...

1 year ago - GlobeNewsWire